The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
